• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

实体瘤中预后不良与SATB1过表达：一项荟萃分析

Poor prognosis and SATB1 overexpression in solid tumors: a meta-analysis.

作者信息

Wang Shengjie, Zeng Junjie, Xiao Rui, Xu Guoxing, Liu Gang, Xiong Disheng, Ye Yongzhi, Chen Borong, Wang Haibin, Luo Qi, Huang Zhengjie

机构信息

Department of Gastrointestinal Surgery, Xiamen Cancer Hospital, The First Affiliated Hospital of Xiamen University, Xiamen, People's Republic of China.

Department of Gastrointestinal Surgery, First Clinical Medical College of Fujian Medical University, Fuzhou, People's Republic of China.

出版信息

Cancer Manag Res. 2018 Jun 8;10:1471-1478. doi: 10.2147/CMAR.S165497. eCollection 2018.

DOI:10.2147/CMAR.S165497
PMID:29922091
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5997180/
Abstract

BACKGROUND

Several previous studies have reported the prognostic value of special -rich sequence-binding protein 1 (SATB1) in solid tumors. However, these studies produced inconsistent results because of their various limitations, including small sample sizes. Here, we describe a meta-analysis based on 17 studies including 3144 patients to search for connections between SATB1 overexpression and overall survival (OS) of patients with solid tumors. Seventeen studies (n = 3144) were assessed in the meta-analysis. Both univariate and multivariate analysis for survival indicated that high SATB1 reactivity significantly predicted poor prognosis. In the multivariate analysis, the combined hazard ratio (HR) for OS was 1.82 (95% confidence interval [CI]: 1.59-2.08, < 0.0001). The pooled HR of the univariate analysis for OS was 1.96 (95% CI: 1.65-2.34, < 0.0001).

METHODS

Studies were identified by an electronic search of PubMed, EMBASE, and Web of Science, including publications prior to April 2017. Pooled HR values for OS were aggregated and quantitatively analyzed in the meta-analysis.

CONCLUSION

The meta-analysis indicated that high SATB1 reactivity is significantly correlated with decreased survival in most cases of solid tumors. In addition, SATB1 shows promise as a prognostic biomarker and novel therapeutic target on the basis of its expression level in solid tumors.

摘要

背景

此前已有多项研究报道了富含特殊序列结合蛋白1（SATB1）在实体瘤中的预后价值。然而，由于样本量小等各种局限性，这些研究结果并不一致。在此，我们基于17项研究（共3144例患者）进行荟萃分析，以探寻SATB1过表达与实体瘤患者总生存期（OS）之间的关联。在这项荟萃分析中评估了17项研究（n = 3144）。生存的单因素和多因素分析均表明，高SATB1反应性显著预示着预后不良。在多因素分析中，OS的合并风险比（HR）为1.82（95%置信区间[CI]：1.59 - 2.08，P < 0.0001）。OS单因素分析的合并HR为1.96（95%CI：1.65 - 2.34，P < 0.0001）。

方法

通过对PubMed、EMBASE和Web of Science进行电子检索来识别研究，包括2017年4月之前发表的文献。在荟萃分析中汇总并定量分析OS的合并HR值。

结论

荟萃分析表明，在大多数实体瘤病例中，高SATB1反应性与生存率降低显著相关。此外，基于SATB1在实体瘤中的表达水平，它有望成为一种预后生物标志物和新型治疗靶点。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a6c5/5997180/9dff7bb3a999/cmar-10-1471Fig6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a6c5/5997180/c405f4832dc9/cmar-10-1471Fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a6c5/5997180/d849299db0d1/cmar-10-1471Fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a6c5/5997180/6988330f31da/cmar-10-1471Fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a6c5/5997180/4fab52746a10/cmar-10-1471Fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a6c5/5997180/8b51db626c82/cmar-10-1471Fig5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a6c5/5997180/9dff7bb3a999/cmar-10-1471Fig6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a6c5/5997180/c405f4832dc9/cmar-10-1471Fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a6c5/5997180/d849299db0d1/cmar-10-1471Fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a6c5/5997180/6988330f31da/cmar-10-1471Fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a6c5/5997180/4fab52746a10/cmar-10-1471Fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a6c5/5997180/8b51db626c82/cmar-10-1471Fig5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a6c5/5997180/9dff7bb3a999/cmar-10-1471Fig6.jpg

相似文献

1
Poor prognosis and SATB1 overexpression in solid tumors: a meta-analysis.实体瘤中预后不良与SATB1过表达：一项荟萃分析
Cancer Manag Res. 2018 Jun 8;10:1471-1478. doi: 10.2147/CMAR.S165497. eCollection 2018.
2
CDC20 overexpression leads to poor prognosis in solid tumors: A system review and meta-analysis.CDC20过表达导致实体瘤预后不良：一项系统评价和荟萃分析。
Medicine (Baltimore). 2018 Dec;97(52):e13832. doi: 10.1097/MD.0000000000013832.
3
Prognostic and Clinicopathological Significance of SATB1 in Colorectal Cancer: A Meta-Analysis.SATB1在结直肠癌中的预后及临床病理意义：一项Meta分析
Front Physiol. 2018 May 15;9:535. doi: 10.3389/fphys.2018.00535. eCollection 2018.
4
The role of SOX2 overexpression in prognosis of patients with solid tumors: A meta-analysis and system review.SOX2过表达在实体瘤患者预后中的作用：一项荟萃分析和系统评价。
Medicine (Baltimore). 2020 Mar;99(13):e19604. doi: 10.1097/MD.0000000000019604.
5
Prognostic significance of SATB1 in gastrointestinal cancer: a meta-analysis and literature review.SATB1在胃肠道癌中的预后意义：一项荟萃分析及文献综述
Oncotarget. 2017 Jul 18;8(29):48410-48423. doi: 10.18632/oncotarget.16867.
6
Prognostic role of DEK in human solid tumors: a meta-analysis.DEK在人类实体瘤中的预后作用：一项荟萃分析。
Oncotarget. 2017 Jul 29;8(58):98985-98992. doi: 10.18632/oncotarget.19684. eCollection 2017 Nov 17.
7
PBK/TOPK overexpression and survival in solid tumors: A PRISMA-compliant meta-analysis.PBK/TOPK在实体瘤中的过表达与生存：一项遵循PRISMA标准的荟萃分析。
Medicine (Baltimore). 2019 Mar;98(10):e14766. doi: 10.1097/MD.0000000000014766.
8
Prognostic value of ZEB-1 in solid tumors: a meta-analysis.ZEB-1 在实体瘤中的预后价值：一项荟萃分析。
BMC Cancer. 2019 Jun 27;19(1):635. doi: 10.1186/s12885-019-5830-y.
9
Role of CXCR7 as a Common Predictor for Prognosis in Solid Tumors: a Meta-Analysis.CXCR7作为实体瘤预后的共同预测指标的作用：一项荟萃分析
J Cancer. 2018 Aug 6;9(17):3138-3148. doi: 10.7150/jca.25377. eCollection 2018.
10
The Prognostic Value of Decreased LKB1 in Solid Tumors: A Meta-Analysis.实体瘤中LKB1降低的预后价值：一项荟萃分析。
PLoS One. 2016 Apr 1;11(4):e0152674. doi: 10.1371/journal.pone.0152674. eCollection 2016.

引用本文的文献

1
Statins exhibit anti-tumor potential by modulating Wnt/β-catenin signaling in colorectal cancer.他汀类药物通过调节结直肠癌中的Wnt/β-连环蛋白信号通路展现出抗肿瘤潜力。
Oncotarget. 2025 Jul 21;16:562-581. doi: 10.18632/oncotarget.28755.
2
Characterization and Efficacy of a Nanomedical Radiopharmaceutical for Cancer Treatment.一种用于癌症治疗的纳米医学放射性药物的表征与疗效
ACS Omega. 2023 Jan 4;8(2):2357-2366. doi: 10.1021/acsomega.2c06755. eCollection 2023 Jan 17.
3
FOXP3 Isoforms Expression in Cervical Cancer: Evidence about the Cancer-Related Properties of FOXP3Δ2Δ7 in Keratinocytes.

本文引用的文献

1
Expression of SATB1 and HER2 in breast cancer and the correlations with clinicopathologic characteristics.SATB1和HER2在乳腺癌中的表达及其与临床病理特征的相关性。
Diagn Pathol. 2015 May 9;10:50. doi: 10.1186/s13000-015-0282-4.
2
Pilot study special AT-rich sequence-binding protein 1 investigating as a potential biomarker for esophageal squamous cell carcinoma.探索富含AT序列结合蛋白1作为食管鳞状细胞癌潜在生物标志物的初步研究
Dis Esophagus. 2016 Aug;29(6):621-6. doi: 10.1111/dote.12365. Epub 2015 May 8.
3
Divergent expression patterns of SATB1 mRNA and SATB1 protein in colorectal cancer and normal tissues.
叉头框蛋白3（FOXP3）亚型在宫颈癌中的表达：关于角质形成细胞中FOXP3Δ2Δ7与癌症相关特性的证据
Cancers (Basel). 2023 Jan 5;15(2):347. doi: 10.3390/cancers15020347.
4
SATB1 protein is associated with the epithelial‑mesenchymal transition process in non‑small cell lung cancers.SATB1 蛋白与非小细胞肺癌中的上皮-间充质转化过程有关。
Oncol Rep. 2021 Jun;45(6). doi: 10.3892/or.2021.8069. Epub 2021 May 6.
5
SATB1 Knockdown Inhibits Proliferation and Invasion and Decreases Chemoradiation Resistance in Nasopharyngeal Carcinoma Cells by Reversing EMT and Suppressing MMP-9.SATB1 敲低通过逆转 EMT 和抑制 MMP-9 抑制鼻咽癌细胞的增殖、侵袭和降低放化疗耐药性。
Int J Med Sci. 2021 Jan 1;18(1):42-52. doi: 10.7150/ijms.49792. eCollection 2021.
6
The Role of SATB1 in Tumour Progression and Metastasis.SATB1 在肿瘤进展和转移中的作用。
Int J Mol Sci. 2019 Aug 25;20(17):4156. doi: 10.3390/ijms20174156.
7
Decreased SATB1 expression promotes AML cell proliferation through NF-κB activation.SATB1表达降低通过激活NF-κB促进急性髓系白血病细胞增殖。
Cancer Cell Int. 2019 May 17;19:134. doi: 10.1186/s12935-019-0850-x. eCollection 2019.
SATB1 mRNA和SATB1蛋白在结直肠癌组织与正常组织中的表达模式差异。
Tumour Biol. 2015 Jun;36(6):4441-52. doi: 10.1007/s13277-015-3084-0. Epub 2015 Jan 21.
4
SATB1 overexpression regulates the development and progression in bladder cancer through EMT.SATB1过表达通过上皮-间质转化调节膀胱癌的发生发展。
PLoS One. 2015 Feb 23;10(2):e0117518. doi: 10.1371/journal.pone.0117518. eCollection 2015.
5
Global cancer statistics, 2012.全球癌症统计数据，2012 年。
CA Cancer J Clin. 2015 Mar;65(2):87-108. doi: 10.3322/caac.21262. Epub 2015 Feb 4.
6
Overexpression of special AT-rich sequence-binding protein 1 in endometrial cancer: a clinicopathologic study.特异性富含AT序列结合蛋白1在子宫内膜癌中的过表达：一项临床病理研究
Int J Gynecol Cancer. 2015 Jan;25(1):4-11. doi: 10.1097/IGC.0000000000000314.
7
SATB1 is an independent prognostic factor in radically resected upper gastrointestinal tract adenocarcinoma.SATB1是根治性切除的上消化道腺癌的一个独立预后因素。
Virchows Arch. 2014 Dec;465(6):649-59. doi: 10.1007/s00428-014-1667-6. Epub 2014 Oct 19.
8
Prognostic and treatment predictive significance of SATB1 and SATB2 expression in pancreatic and periampullary adenocarcinoma.SATB1和SATB2表达在胰腺和壶腹周围腺癌中的预后及治疗预测意义
J Transl Med. 2014 Oct 17;12:289. doi: 10.1186/s12967-014-0289-8.
9
Increased expressions of SATB1 and S100A4 are associated with poor prognosis in human colorectal carcinoma.SATB1和S100A4的表达增加与人类结直肠癌的不良预后相关。
APMIS. 2015 Feb;123(2):93-101. doi: 10.1111/apm.12310. Epub 2014 Sep 25.
10
Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.全球癌症发病与死亡：GLOBOCAN 2012 数据源、方法与主要模式。
Int J Cancer. 2015 Mar 1;136(5):E359-86. doi: 10.1002/ijc.29210. Epub 2014 Oct 9.